Teva Pharmaceutical Industries Ltd
Change company Symbol lookup
Select an option...
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
ON ON Semiconductor Corp
EQNR Equinor ASA
HNORF Harvey Norman Holdings Ltd
MS Morgan Stanley

Based in Israel
Company profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Moderna's shares rise on vaccine manufacturing deal

7:59 am ET May 1, 2020 (MarketWatch)

Shares of Moderna Inc. (MRNA) gained 2.4% in premarket trading on Friday after the company announced a 10-year manufacturing deal with Lonza Group AG for its COVID-19 vaccine as well as its other vaccine candidates. The companies plan to set up manufacturing facilities in Switzerland, where Lonza is based, and the U.S., where they plan to make the first batch of the investigational vaccine by July. "The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale," Lonza chairman Albert Baehny said in a statement. Moderna has conducted the Phase 1 trial of its COVID-19 vaccine; a Phase 2 study is expected to begin in the second quarter. There are no proven vaccines that prevent infections of the novel coronavirus. Year-to-date, Moderna's stock has soared 135.1%, while shares of Lonza have gained 19.8%. The S&P 500 is down 9.8%.

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

May 01, 2020 07:59 ET (11:59 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.